757
Editorial
References 10.
11.
12.
13.
14.
15.
16.
17.
Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393 – 1402. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Ju¨ni P, Scho¨mig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012;33:1214–1222. Haude M, Erbel R, Erne P, Verheye S, Degen H, Bo¨se D, Vermeersch P, Wijnbergen I, Weissman N, Prati F, Waksman R, Koolen J. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013;381:836 – 844. Kocˇka V, Maly´ M, Budeˇsˇ´ınsky´ T, Lisa L, Prodanov P, Tousˇek P, Jarkovsky´ J, Widimsky´ P. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘PRAGUE 19’. Eur Heart J 2014;35:787–794. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, Nauta ST, Ishibashi Y, Lenzen MJ, Ligthart J, Schultz C, Regar E, de Jaegere PP, Serruys PW, Zijlstra F, van Geuns RJ. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction. BVS STEMI FIRST Study. Eur Heart J 2014;35:777 –786. Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, Chan KH, Tan HC, Low AF. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention 2013;9: 501 –504. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, Mu¨nzel T. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 2013;pii: 20130825-02. [Epub ahead of print] Dudek D, Rzeszutko L, Lekston A, Zmudka K, Gil R, Dobrzycki S, Kleinrok A, Witkowsi A, Ciecwierz D, Lesiak M, Ochala A, Wojakoswki W, Przewlocki T, Gasior M, Grajek S, Zasada W, Depukat R, Partyka L. Bioserorbable vascular scaffolds in patients with acute coronary syndrome. The multicenter registry in Poland (POLAR ACS). EuroPCR 2013 (oral presentation). Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, Costa JR Jr, Chamie D, Abizaid AS, Pinto I, Morrison L, Toyloy S, Bhat V, Yan J, Abizaid A. A next-generation bioresorbable coronary scaffold system—from bench to first clinical evaluation: six- and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv 2013;in press:doi:10.1016/j.jcin.2013.07.007
INTERACTIVE CARDIOVASCULAR FLASHLIGHT
doi:10.1093/eurheartj/eht473 Online publish-ahead-of-print 13 November 2013
.............................................................................................................................................................................
A patient with chest pain during dobutamine stress echocardiography Rami El Mahmoud*, Nicolas Mansencal, and Olivier Dubourg Ambroise Pare´ Hospital, Assistance publique-Hoˆpitaux de Paris, Boulogne-Billancourt, France
* Corresponding author. Tel: +33 149095624, Fax: +33 149095344, Email: [email protected]
A 57-year-old male without any significant past medical history is admitted to the intensive care unit for a suspicion of acute coronary syndrome. He is a non-smoker and mentioned a mild hypercholesterolaemia. He reports an acute constrictive rest chest pain with left arm radiation, lasting 45 min and spontaneously resolving. Physical examination was normal. Biological tests were normal with no inflammatory syndrome and no increase in troponin I at admission and 6 h later. ECG and transthoracic echocardiography at admission were normal. He had no recurrence of chest pain during the monitoring period. The patient was discharged after 24 h with aspirin 75 mg and atorvastatin 40 mg. He was readmitted for a dobutamine stress echocardiography. At the maximal dose of dobutamine (40 mg/kg/min), we observed a recurrence of chest pain associated with wall motion asynergy in inferior segments followed by an ST-segment elevation on ECG in the inferior leads. ST-segment elevation resolution was observed after sublingual nitroglycerine and we performed urgent coronary angiography. Coronary angiogram showed a normal left coronary artery. The angiogram of the right coronary artery showed moderate stenosis at the third segment. After administration of intracoronary nitroglycerine, coronary angiogram showed nearly complete disappearance of the third segment stenosis. Explore the full case and MCQs on the ESC website at http://www.escardio.org/education/eLearning/case-based. Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2013. For permissions please email: [email protected]
Downloaded from http://eurheartj.oxfordjournals.org/ by guest on November 15, 2015
1. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable coronary scaffolds: a novel device-based solution in search of its clinical need. Eur Heart J 2014;35:753 –757. 2. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns R-J, Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel Hebert K, Rapoza R, Ormiston JA. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014;in press. 3. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion andrestenosisafter transluminal angioplasty. N Engl J Med 1987;316:701–706. 4. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773 –1780. 5. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362: 1663– 1674. 6. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Juni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomized non-inferiority trial. Lancet 2011;378:1940 –1948. 7. Iqbal J, Sumaya W, Tatman V, Parviz Y, Morton AC, Grech ED, Campbell S, Storey RF, Gunn J. Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. EuroIntervention 2013;9: 62 –69. 8. Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Boersma E, Vranckx P, McFadden E, Serruys PW, O’Neil WW, Jorissen B, Van Leeuwen F, Steg PG; PROTECT Steering Committee and Investigators. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, openlabel, controlled trial. Lancet 2012;380:1396 –1405. 9. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo F, Kimura T, Briguori C, Sabate` M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C,
Editorial
References 10.
11.
12.
13.
14.
15.
16.
17.
Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393 – 1402. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Ju¨ni P, Scho¨mig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012;33:1214–1222. Haude M, Erbel R, Erne P, Verheye S, Degen H, Bo¨se D, Vermeersch P, Wijnbergen I, Weissman N, Prati F, Waksman R, Koolen J. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013;381:836 – 844. Kocˇka V, Maly´ M, Budeˇsˇ´ınsky´ T, Lisa L, Prodanov P, Tousˇek P, Jarkovsky´ J, Widimsky´ P. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘PRAGUE 19’. Eur Heart J 2014;35:787–794. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, Nauta ST, Ishibashi Y, Lenzen MJ, Ligthart J, Schultz C, Regar E, de Jaegere PP, Serruys PW, Zijlstra F, van Geuns RJ. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction. BVS STEMI FIRST Study. Eur Heart J 2014;35:777 –786. Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, Chan KH, Tan HC, Low AF. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention 2013;9: 501 –504. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, Mu¨nzel T. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 2013;pii: 20130825-02. [Epub ahead of print] Dudek D, Rzeszutko L, Lekston A, Zmudka K, Gil R, Dobrzycki S, Kleinrok A, Witkowsi A, Ciecwierz D, Lesiak M, Ochala A, Wojakoswki W, Przewlocki T, Gasior M, Grajek S, Zasada W, Depukat R, Partyka L. Bioserorbable vascular scaffolds in patients with acute coronary syndrome. The multicenter registry in Poland (POLAR ACS). EuroPCR 2013 (oral presentation). Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, Costa JR Jr, Chamie D, Abizaid AS, Pinto I, Morrison L, Toyloy S, Bhat V, Yan J, Abizaid A. A next-generation bioresorbable coronary scaffold system—from bench to first clinical evaluation: six- and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv 2013;in press:doi:10.1016/j.jcin.2013.07.007
INTERACTIVE CARDIOVASCULAR FLASHLIGHT
doi:10.1093/eurheartj/eht473 Online publish-ahead-of-print 13 November 2013
.............................................................................................................................................................................
A patient with chest pain during dobutamine stress echocardiography Rami El Mahmoud*, Nicolas Mansencal, and Olivier Dubourg Ambroise Pare´ Hospital, Assistance publique-Hoˆpitaux de Paris, Boulogne-Billancourt, France
* Corresponding author. Tel: +33 149095624, Fax: +33 149095344, Email: [email protected]
A 57-year-old male without any significant past medical history is admitted to the intensive care unit for a suspicion of acute coronary syndrome. He is a non-smoker and mentioned a mild hypercholesterolaemia. He reports an acute constrictive rest chest pain with left arm radiation, lasting 45 min and spontaneously resolving. Physical examination was normal. Biological tests were normal with no inflammatory syndrome and no increase in troponin I at admission and 6 h later. ECG and transthoracic echocardiography at admission were normal. He had no recurrence of chest pain during the monitoring period. The patient was discharged after 24 h with aspirin 75 mg and atorvastatin 40 mg. He was readmitted for a dobutamine stress echocardiography. At the maximal dose of dobutamine (40 mg/kg/min), we observed a recurrence of chest pain associated with wall motion asynergy in inferior segments followed by an ST-segment elevation on ECG in the inferior leads. ST-segment elevation resolution was observed after sublingual nitroglycerine and we performed urgent coronary angiography. Coronary angiogram showed a normal left coronary artery. The angiogram of the right coronary artery showed moderate stenosis at the third segment. After administration of intracoronary nitroglycerine, coronary angiogram showed nearly complete disappearance of the third segment stenosis. Explore the full case and MCQs on the ESC website at http://www.escardio.org/education/eLearning/case-based. Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2013. For permissions please email: [email protected]
Downloaded from http://eurheartj.oxfordjournals.org/ by guest on November 15, 2015
1. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable coronary scaffolds: a novel device-based solution in search of its clinical need. Eur Heart J 2014;35:753 –757. 2. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns R-J, Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel Hebert K, Rapoza R, Ormiston JA. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014;in press. 3. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion andrestenosisafter transluminal angioplasty. N Engl J Med 1987;316:701–706. 4. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773 –1780. 5. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362: 1663– 1674. 6. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Juni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomized non-inferiority trial. Lancet 2011;378:1940 –1948. 7. Iqbal J, Sumaya W, Tatman V, Parviz Y, Morton AC, Grech ED, Campbell S, Storey RF, Gunn J. Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. EuroIntervention 2013;9: 62 –69. 8. Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Boersma E, Vranckx P, McFadden E, Serruys PW, O’Neil WW, Jorissen B, Van Leeuwen F, Steg PG; PROTECT Steering Committee and Investigators. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, openlabel, controlled trial. Lancet 2012;380:1396 –1405. 9. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo F, Kimura T, Briguori C, Sabate` M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C,
